Substance + claimed effects

Mycoprotein is the dried, textured biomass of the filamentous fungus Fusarium venenatum strain A3/5, grown by continuous fermentation in a stirred-tank bioreactor on a glucose-and-ammonia feedstock, heat-treated to lower nucleic acid content, then bound (usually with egg white, sometimes with potato protein in vegan SKUs) into mince, pieces, fillets, sausages, nuggets, and burgers. It has been sold at retail in the UK since 1985 under the Quorn brand and has held US GRAS status since 2002 Coelho 2020. The wet-weight composition is roughly 11 g protein, 6 g fibre, 2.9 g fat (of which 0.7 g saturated), 85 kcal per 100 g; on a dry basis it is about 45% protein and 25% fibre Coelho 2020. The fibre is structurally distinctive: a fungal cell-wall complex of roughly two-thirds β-1,3/1,6-glucan and one-third chitin (a β-1,4-linked N-acetylglucosamine polymer) Colosimo 2024 — neither of which is found at meaningful levels in either animal meats or the staple plant proteins. The amino acid profile is complete; PDCAAS is reported at 0.91–1.00 across age groups and the bioavailability of individual amino acids is comparable to milk Coelho 2020.

This entry covers the consequences of eating mycoprotein products (Quorn and equivalents) regularly enough to displace red, processed, or white meat from the diet: serum LDL cholesterol, postprandial glucose and insulin, satiety and ad libitum energy intake at the next meal, muscle protein synthesis, the gut microbiome (composition and short-chain fatty acid output), and the allergy / sensitization risk that distinguishes mycoprotein from every other mainstream protein source.

Evidence by addressing question

mechanism

Cholesterol-lowering mechanism is the fibre, not the protein. The cell-wall β-glucan binds bile acids in the small intestine, increasing their faecal excretion; the liver compensates by converting more cholesterol to bile, lowering hepatic LDL-receptor downregulation and reducing circulating LDL — the same bile-acid-sequestration pathway oat β-glucan acts through, plus an additional contribution from chitin, which has independent hypocholesterolaemic activity in animal models Coelho 2020. The displacement effect compounds this: when mycoprotein replaces red and processed meat one-for-one, saturated fat intake drops sharply (a 240 g/d swap removes ~10–15 g SFA daily) Farsi 2023a.

Glycaemic / insulinaemic mechanism is the same fibre matrix slowing gastric emptying and small-intestinal nutrient absorption, plus an apparently independent effect on first-phase insulin secretion; mycoprotein meals lower postprandial insulin without raising GLP-1 or PYY, suggesting the suppression is gut-luminal viscosity / absorption-rate rather than incretin-mediated Bottin 2016.

Satiety mechanism is plausibly the same delayed nutrient absorption signalling sustained luminal nutrient delivery to the ileum, but the marker-set in Bottin et al. did not move; the satiety effect is real and replicated but the proximate signal is still unclear Bottin 2016 Coelho 2020.

Muscle protein synthesis. Mycoprotein is a complete protein with a leucine content of ~9% of total amino acids and bioavailability comparable to milk; peripheral amino acid appearance after a mycoprotein bolus is slower than after concentrated milk protein (the fibre matrix slows digestion), but the area-under-the-curve and the resulting myofibrillar fractional synthetic rate are at least equivalent and, in young men matched on leucine, higher than milk protein Monteyne 2020.

Microbiome. The fibre fraction reaches the colon largely intact. Bacteroides species carry CAZymes that cleave the β-1,3/1,6-glucan backbone, releasing oligosaccharides that cross-feed Bifidobacterium and Lactobacillus; chitin is more recalcitrant but partially fermented by Bacteroides and some Lachnospiraceae. End-products include acetate, propionate, and butyrate Colosimo 2024 Farsi 2023b.

Allergy. Two characterised allergens dominate: a fungal acidic ribosomal protein (P2) cross-reactive with mould and yeast antigens, and a 65-kDa heat-stable glycoprotein. Sensitization may pre-exist via airborne mould exposure (the Quorn-allergic patient first reported in 2003 was a known mould-allergic atopic) Hoek 2003, or develop on repeated dietary exposure — most reported cases in the CSPI series describe reactions appearing only after several months of regular consumption Jacobson 2018.

evidence

LDL cholesterol. The cholesterol-lowering effect is the most-replicated outcome. The original 1992 Turnbull trial (n=21, 130 g/d cookies for 8 weeks, free-living) reported a 13% drop in LDL versus a 7% drop on isocaloric control, in normocholesterolaemic adults Turnbull 1992. The Mycomeat crossover (n=20 metabolically healthy men, 240 g/d mycoprotein replacing 240 g/d red and processed meat for 14 days) gave a 12.3% LDL reduction and 6.74% total cholesterol reduction from baseline on mycoprotein, with no triglyceride change Farsi 2023a. Pavis et al. (2024), the only RCT in overweight, hypercholesterolaemic adults eating mycoprotein in a free-living setting (4 weeks displacing usual meat/fish), found a 10% LDL drop and 6% non-HDL drop versus control Pavis 2024. The 2023 Cherta-Murillo meta-analysis (9 trials, n=178, mean 13 days) confirms a pooled total-cholesterol reduction of −0.55 mmol/L (95% CI −0.85 to −0.26) on mycoprotein versus control; the LDL-specific pooled estimate didn't reach significance, but the meta-analysis's contributing trials were almost all under 4 weeks and most fed isocaloric, not displacement, designs — the larger and longer Pavis trial postdates it Cherta-Murillo 2023.

Postprandial glucose / insulin. Bottin et al. (2016) — n=55 overweight/obese adults, acute crossover, three mycoprotein doses (low/medium/high) vs an isocaloric chicken meal — found mycoprotein lowered insulin AUC dose-dependently (−8% / −12% / −21%) with no GLP-1 or PYY change, and reduced ad libitum energy intake at the next meal by ~10% (~280 kJ) at the high dose Bottin 2016. Cherta-Murillo et al. (2025) — n=20 adults with type 2 diabetes, double-blind RCT — found mycoprotein and guar gum each independently lowered postprandial glucose, with an additive effect when combined; both also improved an oral-glucose-tolerance index of insulin sensitivity Cherta-Murillo 2025.

Satiety / energy intake. The Bottin acute crossover is the strongest single piece of evidence (10% next-meal energy intake reduction at the high mycoprotein dose vs chicken) Bottin 2016; earlier acute trials by the same group and the systematic review consistently show small-but-real reductions in ad libitum intake and self-reported hunger Coelho 2020 Cherta-Murillo 2023. No chronic body-weight RCT in free-living adults has measured weight loss as a primary endpoint, so the satiety signal hasn't been tested for translation into clinically meaningful body-composition change.

Muscle protein synthesis. Three Exeter Nutritional Physiology Group RCTs span the bolus → diet evidence ladder. Monteyne et al. (2020) — n=20 resistance-trained young men, single 70 g protein bolus matched on leucine to a 40 g milk-protein bolus — found mycoprotein stimulated myofibrillar FSR more than milk protein at rest (+47%) and after exercise (+63%) Monteyne 2020. Monteyne et al. (2021) — n=19 older adults (65–86 y), 3-day controlled isonitrogenous diet — found a mycoprotein-based vegan diet supported equivalent daily myofibrillar FSR to an omnivorous diet at the same protein dose Monteyne 2021. Companion work in young adults found the same equivalence and equivalent hypertrophy gains over 10 weeks of resistance training Coelho 2020.

Microbiome / SCFA. The Mycomeat trial's primary endpoint was faecal genotoxicity, and mycoprotein lowered it versus red/processed meat; secondary endpoints showed increased relative abundance of Bacteroides, Roseburia, and Akkermansia and a rise in total faecal SCFA Farsi 2023b. Colosimo et al. (2024) confirmed in an INFOGEST + colonic-fermentation in-vitro model that mycoprotein selectively enriches Bacteroides ovatus and B. uniformis (β-glucan degraders) with SCFA production comparable to oat fibre at 72 h Colosimo 2024. Chronic in-vivo trials remain short (≤4 weeks); long-term effects on community stability are not established.

Allergy / sensitization. The 2018 Jacobson & DePorter case-series of 1,752 web-submitted adverse reactions to Quorn products is the largest dataset: 312 were classified as allergic (urticaria, angioedema, anaphylaxis, including one fatality), 1,692 had GI symptoms (vomiting/diarrhoea typically within 1 hour), and 188/312 (60%) of those with allergic reactions reported repeated reactions on re-exposure. Onset within 1 hour in 46% suggests an IgE-mediated mechanism in a meaningful subset, distinct from food-poisoning-pattern explanations Jacobson 2018. The Hoek case (2003) characterised one cross-reactive epitope (Fusarium acidic ribosomal protein P2) in a mould-allergic atopic Hoek 2003. Prevalence in the general population is unknown — the CSPI dataset is self-reported and the denominator (Quorn-exposed adults) is uncountable — but estimates range from "very rare" (manufacturer position, ~1 in 146,000 servings) to "comparable to peanut or shellfish sensitization on per-capita exposure" (CSPI position).

protocol

The intervention trials cluster around 100–240 g/day of mycoprotein-containing product, displacing an equivalent weight of meat 3–7 times per week. Pavis 2024 used "180 g/day mean intake" across a 4-week intervention with no fixed meal pattern Pavis 2024; Mycomeat used 240 g/d as a hard substitution for 14 days Farsi 2023a; Bottin's acute trials used 44–132 g per meal Bottin 2016. The dose-response data suggest the satiety / insulin effect scales with dose within the tested range; no upper ceiling has been characterised. The MPS trials use single boluses delivering 25–35 g mycoprotein protein (equivalent to ~70 g dry mycoprotein, or 300–400 g hydrated product), matched on leucine to a comparator Monteyne 2020.

A practical reader-facing protocol that maps onto the trial evidence: swap one meat meal per day for a Quorn equivalent (a 150–200 g portion of mince, fillet, or pieces). Three swaps a week is the threshold most studies cross to reach a cholesterol effect; daily swaps produce the larger effect sizes seen in Pavis and Mycomeat.

contraindications

Two real ones. (1) Mould or yeast sensitization. The Fusarium acidic ribosomal protein P2 is cross-reactive with airborne moulds; mould-allergic and Candida-sensitized atopics are at elevated baseline risk for first-exposure reactions Hoek 2003 Jacobson 2018. (2) Egg allergy applies to most retail Quorn SKUs, which use egg white as a binder — only the vegan-labelled range uses potato protein. There is no contraindication on the meta's closed-vocabulary list that maps cleanly to "Quorn allergy after repeat exposure" — this is a population not yet recognised as a clinical contraindication category. Mycoprotein contains no gluten and no soy.

misconceptions

The widely-repeated framing of Quorn as "ultra-processed" — and therefore lumped in with formulated meat analogues like Beyond Burger — misses the substance distinction. Mycoprotein is a single-organism whole biomass: the fungus is grown, harvested, heat-treated, drained, and bound. It is closer in processing structure to tofu (a single-substrate coagulate) than to a reconstructed meat analogue (an emulsion of isolated soy/pea protein, methylcellulose, coconut oil, beet juice, and flavourings). The cardiovascular evidence treats it accordingly — every chronic trial cited above measured a benefit on substitution for meat, the opposite direction from the UPF-and-cardiovascular-disease literature Farsi 2023a Pavis 2024. A second misconception is that the protein quality is inferior because it's plant-derived: by PDCAAS, DIAAS-leucine, and direct MPS measurement, mycoprotein matches or exceeds milk protein per gram Monteyne 2020 Coelho 2020.

alternatives

The realistic substitution slate for "regular meat-displacing protein-dense food" is tofu, tempeh, seitan, legumes (lentils, beans), reformulated soy/pea meat analogues (Beyond, Impossible), and unprocessed white meat. Mycoprotein's distinctive vs each: PDCAAS-equivalent to whey/milk (most plant proteins are lysine-limited and sit at 0.6–0.85); fibre content per gram protein is higher than tofu or seitan and comes with the β-glucan + chitin profile that no other mainstream food carries; saturated fat is far below red/processed meat (0.7 g vs 8–12 g per 100 g) and competitive with the leanest poultry. The cardiovascular evidence base is unusually deep relative to alternative protein candidates: only soy approaches it in trial volume. The trade-offs are cost (Quorn typically retails 1.5–2× tofu by weight), the egg-white binder in the non-vegan range, and the allergy risk that no comparator carries.

failure-modes

The dominant failure mode is texture aversion driving non-adherence: the meat-mimicking SKUs (mince, sausages, nuggets) hold up if treated like meat (don't overcook; brown before saucing); the fillet/cutlet SKUs go rubbery if overcooked. The cholesterol benefit is contingent on actual displacement — eating Quorn alongside the usual meat intake fails on bioactivity grounds (no SFA reduction) even if the protein and fibre arrive. The second failure mode is the sensitization escalation pattern: a reader who tolerates the first portions but develops urticaria or GI distress on repeat exposure is the population the CSPI dataset describes, and continued exposure past first symptoms is the wrong call Jacobson 2018. The third is the egg-white assumption — buying Quorn pieces under the impression they are vegan is a real and frequent error among new readers.

practicalities

Mycoprotein is sold under multiple brands (Quorn is the dominant; smaller players include Marlow Foods' OEM lines and a growing set of Fusarium-derived analogues). Distribution is best in the UK, Ireland, the Netherlands, Switzerland, Germany, and increasingly the US (Whole Foods, Target, Walmart in major metros). Pricing (US, 2026): mince ~$5–7 per 12 oz pack; pieces and fillets similar. Vegan-labelled SKUs use potato protein in place of egg white; check the panel. Shelf life is several months frozen; once thawed, treat like fresh meat. Most products are pre-cooked and need only 5–8 minutes' reheating.

history

Mycoprotein was developed by Rank Hovis McDougall and ICI from the mid-1960s as a hedge against forecast global protein shortages; the Fusarium strain (originally misidentified as F. graminearum, later correctly identified as F. venenatum A3/5) was isolated from a soil sample in Marlow, Buckinghamshire, in 1967. UK retail launch was 1985 (as Quorn). US GRAS notification was filed in 2001 and accepted in 2002 Coelho 2020. The CSPI petitioned the FDA to revoke GRAS status in 2002, 2011, and again in 2018 on the basis of the adverse-reaction dossier; FDA declined each time, citing the rarity of the events relative to consumption volume Jacobson 2018.

stakes

If the typical reader stays on a meat-default protein pattern when a tolerated swap exists, the missed effect is roughly: ~10% higher LDL than the swap version of them, slightly higher postprandial insulin excursions, lower satiety per kcal at the protein-dense meal, and a less-diverse colonic SCFA-producer profile Pavis 2024 Farsi 2023a Farsi 2023b. These are individually modest; in combination, over decades, they sit upstream of the cardiometabolic-event curve.

payoff

The fastest measurable changes after starting a 3-meals-per-week swap are postprandial insulin (one meal in) and satiety (one meal in); LDL moves on a 2–4-week timescale in trial settings Pavis 2024. The microbiome shift appears within 14 days Farsi 2023b. The MPS evidence says muscle gains during a training block are not sacrificed by the swap, at any age tested Monteyne 2020 Monteyne 2021. Long-term cardiovascular-event reduction is inferred from the LDL effect — direct trial evidence on hard endpoints does not yet exist.

out-of-scope

The environmental case (land, water, GHG) is real and well-replicated but outside this entry's effect-on-body scope. The fungus-as-feedstock biotech adjacent topics (Solar Foods' Solein, Air Protein, Aqua Cultured cellulose-based mycelium fillets) are not Fusarium-derived and have different safety / nutritional dossiers — they warrant their own entries when retail-relevant. The general "meat alternatives and cardiometabolic health" meta-evidence is broader than mycoprotein and belongs in its own entry.

The credibility range

Optimist case. Mycoprotein is one of the most evidence-supported single foods for LDL reduction outside of soluble-fibre supplements: three independent groups (Turnbull, Mycomeat, Pavis) have replicated 10–13% LDL drops in three different populations (normocholesterolaemic, healthy male, hypercholesterolaemic overweight), with a converging meta-analytic total-cholesterol estimate Cherta-Murillo 2023. The mechanism (β-glucan bile-acid sequestration + chitin + saturated-fat displacement) is mechanistically over-determined, so the effect is robust to formulation variation across products. The MPS evidence dismantles the standard "plant protein is inferior" objection. The satiety + glycaemic data position it as one of the rare swaps that improves several cardiometabolic axes simultaneously without a discipline cost. The allergen issue is real but quantitatively comparable to other food allergies: the CSPI dataset's denominator-corrected event rate is well below shellfish or peanut on a per-eater basis, and self-limiting on cessation.

Skeptic case. The chronic LDL trials are short (≤4 weeks) and small (n=20–72); no event-endpoint trial exists; cardiovascular outcomes are inferred from biomarker change. The satiety + body-composition link has never been measured chronically as a primary endpoint, so the "weight management" framing is speculative. The MPS work is concentrated in one research group (Exeter Nutritional Physiology Group), funded in part by Marlow Foods; independent replication is sparse. The allergy / sensitization signal is unique to mycoprotein among major plant proteins, the underlying immunology (cross-reactive mould epitope + de novo sensitization) is exactly the pattern that would worsen with population-level exposure, and the regulatory record (CSPI petitions, multiple country-specific labeling regimes, one documented fatality) is heavier than for any other vegan-or-equivalent protein source. Consumer-acceptability ceiling (texture aversion) caps the realistic adoption rate.

The author's call. The cardiometabolic case is strong enough to recommend as a real swap, not just as a curiosity: LDL is the most replicated outcome in cardiovascular nutrition, three independent RCTs converge on a ~10% drop with a defensible mechanism, and the comparator (red/processed meat) is the highest-evidence dietary risk factor available to substitute against. The MPS evidence resolves the "but plant protein is inferior" objection at protein-doses matched on leucine. The allergen risk is the load-bearing caveat — it is real, distinctive, and not inferable from priors on other plant proteins, so it must be named plainly. Net: meaningful benefit for the population without baseline mould or fungal sensitization, who can swap 3+ meat meals per week; stop on the first urticaria, GI distress, or any anaphylactoid sign; choose vegan-binder SKUs if egg is an issue.

Stakeholder + incentive map

• Marlow Foods / Quorn (Monde Nissin since 2015): commercial incentive to fund clinical research and emphasise the LDL / MPS / fibre evidence; underplay the allergen series. Funds much of the Exeter NPG mycoprotein work.
• Exeter Nutritional Physiology Group (Stephens, Wall, Monteyne): academic prestige + grant continuity from a productive sub-field. Their methodological reputation is intact; conflicts disclosed; effect sizes large enough that funder-bias-only explanations are implausible.
• CSPI (Center for Science in the Public Interest): consumer-advocate incentive that runs in the opposite direction — collecting and publicising the adverse-reaction dossier, petitioning FDA, framing the food as unsafe. Methodology has been criticised (self-report, no denominator), but the dataset is the only large-scale source of post-market surveillance.
• FDA / FSA (UK): regulatory incentive to maintain status quo absent overwhelming evidence; both have considered the dossier and declined to act, allowing labeling adjustments instead.
• Alternative-protein VC / sector: reputational stake in any fungus-derived food category — Quorn's safety record is treated as exemplar for newer entrants (Solar Foods, Nature's Fynd, Meati).
• Cardiovascular nutrition guideline bodies (AHA, NICE, ESC): dietary guidance increasingly endorses meat-displacement for LDL reduction; mycoprotein is named in some guidance as one such substitute. No body has issued a contraindication.

Population variability

• Baseline LDL: larger absolute drops in hypercholesterolaemic readers (Pavis cohort) than normocholesterolaemic; relative drops similar.
• Baseline meat intake: the cardiovascular and microbiome effects depend on displacement — readers eating little or no meat at baseline see a smaller swap effect. The fibre and protein quality benefits persist.
• Atopic background, especially mould / Candida / yeast sensitization: elevated first-exposure allergy risk Hoek 2003.
• Age: MPS equivalence to omnivorous diet holds in both young (20s) and older (65–86) adults Monteyne 2020 Monteyne 2021. The older-adult dose at which leucine threshold is met is higher; mycoprotein gets there at ~35 g protein.
• Type 2 diabetes: the postprandial-glucose benefit is preserved and likely larger in absolute terms Cherta-Murillo 2025.
• Ethnicity: Cherta-Murillo 2025 found independent ethnicity effects on the glucose response, with consistent direction but variable magnitude — under-studied; current trial cohorts are mostly white Northern European.
• Egg-allergic and vegan readers: restricted to the labelled-vegan SKU range; non-vegan Quorn contains egg-white binder.

Knowledge gaps

No chronic (≥3-month) RCT on body composition or hard cardiovascular endpoints exists. The denominator for the allergy rate is unknown; a prospective post-market surveillance registry has never been run. Long-term microbiome stability data (≥6 months) is absent. The dose-response curve for the LDL effect is not characterised between 100 g/d and the trial-tested 240 g/d. The independent contribution of chitin vs β-glucan to bile-acid sequestration has not been isolated in human work. Whether the satiety effect translates to chronic weight change, and whether the postprandial-glucose effect translates to HbA_1c in diabetes, remain unanswered. The immunology of de novo sensitization in non-atopic adults — onset rate, dose threshold, epitope spread — is uncharacterised. Evidence on Fusarium-derived non-Quorn mycoprotein products (the emerging post-2020 OEM range) is currently a one-product extrapolation.

Coverage relative to the brief. The brief named LDL, postprandial glucose and insulin, satiety, muscle protein synthesis, gut microbiome, and allergy/sensitization considerations. All six are covered in the article body — LDL and the swap mechanism lead, postprandial glucose / insulin / satiety land together in the evidence and payoff sections, MPS sits in mechanism and is referenced in misconceptions, microbiome lives in evidence and payoff, and the allergy section is the load-bearing contraindications passage with its own warning callout. Nothing in the brief was dropped.

Rating call: evidence at 3, not 4. Borderline. The cholesterol effect has three independent RCT replications, a 2023 meta-analysis, and a defensible mechanism — that's stronger than the 3 anchor ("small or preliminary studies with a plausible mechanism") and approaches the 4 anchor ("one good RCT or consistent observational data; clinical community is broadly aligned"). I held at 3 because: (a) all chronic trials are short (≤4 weeks) and small (n=20–72); (b) no hard cardiovascular endpoint data exists; (c) the MPS work is concentrated in one (industry-funded) lab; (d) the allergy dossier rests on a self-reported case series without a denominator. The clinical community isn't formally aligned around a specific recommendation yet, even though several guideline bodies name mycoprotein in passing as a meat alternative.

Rating call: longevity at 3. The trial-replicated 10% LDL drop is mechanistically powerful — LDL is the most-validated modifiable cardiovascular risk factor and lifetime LDL exposure tracks closely with event-curve outcomes. A 3 ("meaningful disease-prevention or mortality reduction") reflects this plus the microbiome and saturated-fat displacement contributions. I considered 4 ("large effect; one of the more impactful interventions in the catalogue") and held back because the effect size depends on actual displacement frequency and there's no long-term event-endpoint evidence specifically for mycoprotein.

Rating call: applicability at 4. Mycoprotein is most relevant to the broad meat-eating adult population considering a cardiometabolic swap. Held below 5 because (a) US retail distribution still leaves gaps outside major metros, (b) the strict vegan is restricted to the labelled-vegan SKU subset, (c) mould-allergic readers have an elevated baseline risk, and (d) the cardiovascular benefit is contingent on actual meat displacement, so the small subgroup of readers eating little meat already gains less.

Dream narrative written despite sub-40 score. Overall score lands around 30, so the narrative was optional. I wrote one in the relief / clarity lever (not aspiration) — the lever that fits a "modest swap that compounds" entry. It informed the dek and payoff voice; tagline picked up its blunt cause-and-effect cadence.

Sensitization signal placement. Considered putting the allergy passage earlier (between mechanism and evidence) so a reader skimming top-to-bottom encounters the caveat before the protocol. Held it at contraindications-after-stakes because (a) the action recommendation needs the trial evidence in front of it to land, and (b) the warning callout inside the section is visually distinctive enough to read as the gate even on a skim. The dek and highlights both flag it.

Excluded — environmental footprint. The land-water-GHG case for fungal protein over animal protein is real and well-replicated but outside body-effect scope. Pointed at briefly in out-of-scope; doesn't earn a section of its own here.

Excluded — non-Quorn Fusarium mycoprotein brands. The OEM and emerging-brand landscape is still thin enough on independent trial data that conflating it with Quorn's trial dossier would be dishonest. Flagged in out-of-scope.

Excluded — environmental, biotechnology, broader meat-alternative meta-evidence. Each warrants its own entry. Flagged in out-of-scope as a forward pointer.

Future-link candidates.

• Dietary cholesterol-lowering (whole-diet view) — saturated fat displacement, soluble fibre, plant sterols, fish substitution. Mycoprotein is one lever in this larger pattern.
• Soy / tofu / tempeh as a meat alternative — would let alternatives pick up a clean cross-link.
• Statins as cardiovascular-event reduction — the article's payoff section references the statin conversation; a real entry would close that loop.
• Apparent post-meal slumps / postprandial glycaemia — the energy and focus pitches lean on this; a dedicated entry would carry the cross-reference.
• Newer fungal foods (Solein, Nature's Fynd, Meati) — separate dossiers, separate entries when retail-relevant.

Separate-entry candidates surfaced during writing.

• Cell-wall fibres (β-glucan, chitin) as a class of cholesterol-lowering and microbiome-modulating fibre — would carry the mechanism story across substrates (oats, mycoprotein, mushrooms).
• Food-allergen sensitization across repeated exposure — the "develops the allergy after months of fine eating" pattern isn't unique to Quorn and a dedicated entry would help readers recognise the pattern across foods.

Tagline call. The straight version ("Swap the mince. Drop the cholesterol ~10%. Stop on the first hive.") earns its blunt three-beat shape from the dream narrative's relief lever, but stays in the §2 grammar: present-tense, imperative, no hedging, includes the load-bearing caveat. Considered "Same dinner. Lower cholesterol. Different fungus." — felt less honest because it elides the allergy signal. Chose to keep the caveat in the tagline.